Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
We recommend to our readers a recent article in Medscape Oncology entitled “What’s impeding active surveillance in prostate cancer?” The article is based on a review by Cooperberg et al. in a recent issue of the Journal of Clinical Oncology. However, the full text of that review article is not easily accessible for most patients [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: acceptance, active surveillance, education | 9 Comments »
According to a media release from Adamis Pharmaceuticals, the company has started to enroll patients into a Phase I/IIa clinical trial of APC-100 in men with castration-resistant prostate cancer (CRPC).
Filed under: Drugs in development, Management | Tagged: Adamis, APC-100, casrtation-resistant | Leave a Comment »
The possibility of approval of the Progensa® PCA3 test here in the USA any time soon appears to have received a setback.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Gen-Probe, PCA3, Progensa | Leave a Comment »
Centers apply a variety of inclusion criteria in evaluating the eligibility of patients for management using active surveillance (AS) protocols. The applicability of an immediate, transrectal ultrasound (TRUS)-guided re-biopsy is recommended by a number of centers, but there is no consensus about the need for re-biopsy at this time.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, biopsy, eligibility, repeat | 4 Comments »
As we have noted several times before, databases in selected European nations (most particularly the Scandinavian countries) allow for the possibility of highly accurate analyses of information on the diagnosis, management, and outcomes of prostate cancer (and other disorders) over time based on data from very large numbers of people.
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: Denmark, Diagnosis, mortality, outcome, survival | 3 Comments »
The national rates of participation in clinical trials by cancer patients have never been particularly high. The National Cancer Institute states that, “less than 5 percent of adults diagnosed with cancer each year will get treated through enrollment in a clinical trial.”
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: efficiency, enrollment, post-surgery, trials | 1 Comment »
Clinical guidelines issued by the National Comprehensive Cancer Network recommend that prostate cancer patients being treated with androgen deprivation therapy (ADT) — either alone or in combination with radiation therapy — should be screened for osteoporosis and treatment to prevent deterioration of bone health associated with a decline in bone mineral density.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, DXA, fracture, FRAX, guideline, osteopenia, osteoporesis, Prevention | 4 Comments »
Researchers at the Mayo Clinic have queried their large, nearly 20-year-long database of men who have undergone radical prostatectomy in an attempt to assess the correlation between positive surgical margins at the time of surgery and subsequent occurence of systemic disease or prostate cancer-specific mortality.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: outcome, positive surgical margins, prostate cancer-specific mortality, radical prostatectomy, systemic disease | 4 Comments »
Several weeks ago, the UroToday web site (which used to be free) started to charge a significant annual fee ($139.00) to use their site. The “New” Prostate Cancer InfoLink has learned that (for at least a brief period of time) UroToday is offering patients and consumers a year’s subscription for just $30.00.
Filed under: Uncategorized | Tagged: UroToday | 5 Comments »
Academic research into the side effects of different treatments for localized prostate cancer have long been hampered by the lack of consistently used criteria for the assessment of those side effects at baseline and at defined time-periods post-treatment.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: EBRT, laparoscopic, radiation therapy, radical prostatectomy, RALP, robot-assisted, side effects, surgery | 3 Comments »
This month’s issue of The ASCO Post includes an interview with Dr. Chris Parker, a prostate cancer specialist at the Academic Urology Unit, The Royal Marsden NHS Foundation Trust (one of the UK’s most prestigious prostate cancer units), about the realities of oncology services in general and prostate cancer services in particular in the United [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: National Health Service, NHS, UK | 14 Comments »
“Manserin” is a novel peptide originally derived from a larger secretory protein called secretogranin II. A newly published paper suggests that expression of manserin in human prostate cancer tissues may correlate with risk for clinically significant and progressive forms of prostate cancer.
Filed under: Diagnosis, Management, Risk | Tagged: expression, Gleason, immunohistochemistry, manserin, progression, risk | Leave a Comment »
A new article on the CancerNetwork.com web site has provided a detailed update on the development of cabozantinib (also known as XL184) for the treatment of late stage prostate cancer.
Filed under: Drugs in development | Tagged: cabozantinib, XL184 | 2 Comments »
Data reported earlier this year from the PIVOT study and separately from the long-term Scandinavian study have shown that the surgical treatment of prostate cancer in the patients enrolled in these trials showed no median prostate-cancer specific or overall survival benefit compared to watchful waiting in patients of > 65 years of age.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: "high risk", age, elderly, old, radical prostatectomy, RALP, robot-assisted | 2 Comments »
The full text of a new article on the potential of whole ginger extract (WGE) in the prevention and treatment of of prostate cancer has recently been published in the British Journal of Nutrition.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Prevention, Treatment, Uncategorized | Tagged: extract, ginger, Prevention, Treatment, WGE | 3 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site